echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Amgen's bispecific antibody AMG 570 gets clinical approval in China

    Amgen's bispecific antibody AMG 570 gets clinical approval in China

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The Center for Drug Evaluation (CDE) of the National Medical Products Administration of China recently announced that Amgen's Class 1 new drug, AMG 570, has obtained a clinical trial implied license to develop the treatment of systemic lupus erythematosus (SLE).


    Screenshot source: CDE official website

    Systemic lupus erythematosus is a chronic systemic autoimmune disease with clinical manifestations of multiple system damage symptoms.


    ICOS (also known as CD278) is an immune checkpoint expressed on activated T cells and is a type of co-stimulatory receptor.


    BAFF (B cell activating factor), also known as BLyS (B lymphocyte stimulating factor), can support B cell survival by binding to the BAFF receptor (BAFFR) expressed on B cells.


    AMG 570 is a bispecific antibody developed by Amgen that can target BAFF and ICOSL at the same time.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.